04:50 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
18:00 , Aug 24, 2017 |  BC Innovations  |  Emerging Company Profile

Heartfelt WISPER

HaYa Therapeutics is using antisense oligonucleotides to target the lncRNA WISPER to treat cardiac fibrosis caused by cardiovascular diseases such as myocardial infarction. Because WISPER expression is confined to the heart, the newco is betting...
07:00 , Aug 5, 2013 |  BC Week In Review  |  Company News

Nerviano, Servier deal

Servier paid Nerviano €8 million ($10.6 million) in exchange for an option to license worldwide rights to develop and commercialize preclinical compounds from Nerviano that inhibit TTK protein kinase (TTK; MPS1 ), a cell cycle...
00:41 , Aug 2, 2013 |  BC Extra  |  Company News

Servier, Nerviano in deal for preclinical TTK inhibitors

Servier (Neuilly-sur-Seine, France) paid Nerviano Medical Sciences s.r.l. (Nerviano, Italy) EUR 8 million ($10.6 million) in exchange for an option to license worldwide rights to develop and commercialize preclinical Nerviano compounds that inhibit TTK protein...
08:00 , Feb 21, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Myelodysplastic syndromes (MDS) Retinoblastoma protein (Rb) Studies in mice suggest that manipulating Rb expression in hematopoietic cells could be a strategy...
07:00 , Sep 25, 2000 |  BC Week In Review  |  Company News

Genometrix sales and marketing update

Genometrix launched the VistaExpress Apoptosis and Cell Cycle Regulator and the Growth Factor/Cytokine prefabricated microarrays for use with its ultra-high throughput gene expression analysis services. Genometrix Inc., The Woodlands, Texas   Business: Enabling technology  ...
08:00 , Mar 1, 1999 |  BC Week In Review  |  Clinical News

CV Therapeutics In regulatory update

CVTX received U.S. Patent No. 5,866,702 covering purine inhibitors of cyclin dependent kinase 2 (CDK2) , a cell cycle regulator. The inhibitors could prevent cellular proliferation that occurs following vascular injury, the company said. CV...
08:00 , Mar 30, 1998 |  BC Week In Review  |  Company News

University of Toronto other research news

Canadian researchers reported in The New England Journal of Medicine that mutations in a tumor suppressor gene occur in some patients with multiple primary melanomas. These patients have repeat melanoma of the same tissue type....